NCT02106182 (BPH) is a Phase 4 clinical trial of Silodosin in Nocturia, sponsored by JW Pharmaceutical.

Who is sponsoring NCT02106182?

NCT02106182 is sponsored by JW Pharmaceutical.

What drugs are being tested in NCT02106182?

Interventions in NCT02106182: Silodosin, Laboratory tests, 3-days voiding diary, 12 weeks.

What condition does NCT02106182 study?

NCT02106182 studies Nocturia, Benign Prostatic Hyperplasia.

Is NCT02106182 still recruiting?

NCT02106182 is currently completed. Last updated 10 March 2017.

Last reviewed 2017-03-10 · How we verify

NCT02106182: BPH

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of Silodosin on Nocturia for Patients With Benign Prostatic Hyperplasia

Completed Phase 4 Last updated 10 March 2017

What this trial tests

Phase 4 trial testing Silodosin in Nocturia in 135 participants. Completed in 1 August 2016.

Timeline

2 January 2014

Primary endpoint
2 March 2016

1 August 2016

Quick facts

Lead sponsor	JW Pharmaceutical
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	135
Start date	2 January 2014
Primary completion	2 March 2016
Estimated completion	1 August 2016
Sites	6 locations across South Korea

Drugs / interventions tested

Silodosin (SILODOSIN) — full drug profile →
Laboratory tests
3-days voiding diary
12 weeks

Conditions studied

Nocturia — all drugs for Nocturia →
Benign Prostatic Hyperplasia — all drugs for Benign Prostatic Hyperplasia →

Sponsor

JW Pharmaceutical — full company profile →

Who can join

50 and older, male only, with Nocturia or Benign Prostatic Hyperplasia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to determine safety and efficacy of silodosin, which is a treatment for benign prostatic hyperplasia with high selectivity to α1A-receptor, on patients with benign prostatic hyperplasia accompanied by nocturia.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Silodosin

Trials testing the same drug.

NCT07467343 — Silodosin vs Tamsulosin for LUTS Due to BPH: A Randomized Crossover Trial · Phase 4 · not yet recruiting
NCT06114979 — Silodosin vs Placebo in the Treatment of Female LUTS · Phase 3 · unknown
NCT06999135 — Comparison of Silodosin and Tamsulosin for Medical Expulsive Therapy in Patients With Ureteral Stones · NA · completed
NCT06381206 — Silodosin in Management of Lower Ureteral Stones · Phase 1, PHASE2 · completed
NCT05790902 — COMPARISON OF SILODOSIN AND TAMSULOSIN IN MEDICAL EXPULSIVE THERAPY OF DISTAL URETERIC CALCULI · Phase 1 · completed

Other recruiting trials for Nocturia

Currently open trials in the same condition.

NCT06754189 — Safety and Performance of UCon Patch Electrode · NA · recruiting
NCT06866834 — Examination of the Effect of Nocturia on Pelvic Floor Symptoms, Sleep Parameters and Quality of Life in Women with Urina · recruiting
NCT06091566 — Safety and Performance of UCon Bar Electrode for the Treatment of Overactive Bladder (OAB) and Bowel Dysfunction (BD) · NA · recruiting
NCT05874375 — UCon Treatment of Overactive Bladder (OAB) in Males · NA · recruiting
NCT05604222 — Effect of Behavioral Sleep Intervention on Lower Urinary Tract Symptoms in Older Women · Phase 4 · recruiting

Other JW Pharmaceutical trials

Trials by the same sponsor.

NCT07514780 — To Evaluate the Safety, Pharmacokinetic and Pharmacodynamics of JW0061 in Healthy Volunteers · Phase 1 · not yet recruiting
NCT07378098 — to Evaluate the Efficacy and Safety of KLH-2109 in Patients With Uterine Fibroids and Menorrhagia · Phase 3 · recruiting
NCT07374406 — To Evaluate the Safety and Pharmacokinetic Characteristics in Healthy Volunteers · Phase 1 · recruiting
NCT07442006 — Glycemic Variability of Combination Therapies in T2DM · Phase 4 · recruiting
NCT07036458 — To Evaluate the Mass Balance Recovery, Metabolite Profile and Metabolite Identification in Healthy Male Subjects · Phase 1 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02106182 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by JW Pharmaceutical
Last refreshed: 10 March 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02106182.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing